Skip to main content

Dermatology

PSS.hands_.Raynauds.jpg (keep)

Relevance of Raynaud’s in Systemic Sclerosis

May 18, 2022

Raynaud’s phenomenon (RP) is integral to the diagnosis and management of systemic sclerosis (SSc) patients; a recent analysis suggests that RP should be characterized based on color change and the presence of other symptoms to know whether RP portends more serious manifestations.

Read Article
SpA,RNL,2022

RNL 2022: Spondyloarthritis Spectrum

May 18, 2022

This RheumNow Live 2022 session features highlights from lectures on Spondyloarthritis.



- Microbiome in Spondyloathritis - Jose Scher, MD



- Axial Psoriatic Arthritis - Philip Mease, MD



- Juvenile Spondyloathritis - Pamela Weiss, MD


Read Article
Acne with JAK Inhibitors JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi.https://t.co/ADzaBjgsAN https://t.co/Yydo47UGYl
Dr. John Cush @RheumNow( View Tweet )
May 14, 2022
RheumNow Podcast square

Methotrexate Monitoring (5.13.2022)

May 13, 2022

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Bad news for digitial ulcers in Systemic sclerosis, Readmissions in Lupus and Thrombocytopenia in APL patients.




  1. Risk factors for readmission among 132,400 #SLE hospitalizatiions included

Read Article
Large Korean population study compares pts w/ palmoplantar psoriasis vs psoriasis and PPP pts have more risk for ankylosing spondylitis (aOR 1.37) & Graves dz (aOR 1.4) but lower risk for PsA (aOR 0.54), SLE (0.67); Sjögren (0.70); vitiligo (0.53) https://t.co/0fv2vnFBPf https://t.co/PJMagIeZ2F
Dr. John Cush @RheumNow( View Tweet )
May 07, 2022
Danish case-control registry of 491,274 women shows Psoriasis assoc w/ increased risk of ectopic pregnancy (EP) (OR 1.34), highest in women w/ moderate-to-severe psoriasis (OR 2.77). EP risk was 2.5x higher for women w/ mod--severe PSO https://t.co/vUtNEMDOhr

Dr. John Cush @RheumNow( View Tweet )

May 06, 2022
RheumNow Podcast square

What is JAKne? (5.6.2022)

May 06, 2022

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.




  1. Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14);

Read Article
acne

Acne with JAK Inhibitors

May 05, 2022

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).

Read Article
RheumNow Podcast square

$30 Billion and Counting (4.29.2022)

Apr 29, 2022

Dr. Jack Cush reviews the news and journal reports and takes viewer questions this week.

Read Article
TNRPSA,0426

PsA Journal Club - Fecal Transplant & H2H IXE vs ADA

Apr 27, 2022

Playback now available! Watch our Tuesday Nite Rheumatology, held April 26th, 2022, which featured a Journal Club panel discussion  about two important studies.

Read Article
Cardiovascular risk (CVR) was assessed in Psoriasis (#PSO) & #PSA in multiracial population in S Brazil using the Framingham Risk Score. Compared to controls PSO & PSA had higher FRS (16.3 & 18 vs 10.6) and also increased with age. highttps://bit.ly/3k7ySi8

Dr. John Cush @RheumNow( View Tweet )

Apr 26, 2022
One centers experience with a combined Rheum-Derm Clinic. Among 151 psoriasis patients with suspicious musculoskeletal complaints, 85% were dx w/ PsA - 62% of these PsA was 1st diagnosed. https://t.co/RcQrWaXTWj

Dr. John Cush @RheumNow( View Tweet )

Apr 25, 2022
TNR,controversies,psa

TNR - Controversies in PsA

Apr 20, 2022

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.



The PsA Expert panelists included:



  • Dr. Dafna Gladman, Toronton

  • Dr. Joseph Merola, Boston

  • Dr. Peter
Read Article
TNR,PSA,journal,0412

Now Available: TNR - Psoriatic Arthritis Journal Club

Apr 15, 2022

A recording of this week’s Tuesday Night Rheumatology is now available. This outstanding webinar featured a robust discussion of the EXCEED study and Discover-2 trial, with Drs. Philip Mease, Peter Nash, Jack Cush and Rachel Tate.

Read Article
Large metanalysis looks at Quality of Life outcomes w/ Therapies in #PSA 37 RCTs = 14.115 PsA pts ◾️ bDMARDs > PBO ◾️ bDMARDs = MTX (or Tofa) ◾️ bDMARDs + MTX > MTXhttps://t.co/6DDsVjcdcr https://t.co/ljb6AOH3UK
Dr. John Cush @RheumNow( View Tweet )
Apr 14, 2022
child.guttate.psoriasis

Kids With Psoriasis Maintained with Long Term IL-17A Inhibitor

MedPage Today
Apr 14, 2022

Pediatric patients with moderate-to-severe plaque psoriasis obtained significant improvement in disease status for as long as 2 years with the interleukin (IL)-17A inhibitor ixekizumab (Taltz), long-term follow-up from a randomized trial showed.

Read Article
Combined Clinics for PsA Rheums and derms have long worked together in the management of our patients, but the idea of directly collaborating in a single clinic space was novel at the time. Over the years, it has become my favorite clinic of the week. https://t.co/uY1mZtlvaV https://t.co/5AZ2z2kSVG
Dr. John Cush @RheumNow( View Tweet )
Apr 13, 2022
dementia,brain

Is Alzheimer's Risk Lower With TNF Inhibitors?

MedPage Today
Apr 11, 2022

Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.



Among

Read Article
211 pts presenting w/ hot swollen joint to the ER; 28 w/ septic arthritis; pseudogout 32; gout 50; & others: 101. Predictors of Septic Arthritis: RA (OR 3.4); skin infx (OR 3.3); liver Dz (OR 9.9); knee involv (OR 3.5); immunosuppressive use (OR 3.5) https://t.co/uASovNVOWb https://t.co/Fq3obVDavm
Dr. John Cush @RheumNow( View Tweet )
Apr 05, 2022
heart,cv,meds, events, CVD

Apremilast’s Neutral Effects on Cardiovascular Inflammation

MedPage Today
Apr 04, 2022

An evaluation of a common psoriasis drug's effect on one cardiometabolic risk factor instead showed a favorable impact on a different one.



The randomized trial showed that apremilast (Otezla) did not significantly affect aortic vascular inflammation but did lead to a statistically

Read Article
psoriasis,arms,pain

Towards More Uniform Methotrexate Dosing in Psoriasis

MedPage Today
Apr 01, 2022

With overwhelming support from some 200 experts worldwide, dosing of methotrexate (MTX) for psoriasis should start at 15 mg/week for most adults, though lower in those considered "vulnerable" and in children, according to a new consensus statement.

Read Article
Danish study of opioids in psoriasis (n 4016), PsA (847) & controls (3490). Opioid Use within 12 months seen in 9% general population, 14.2% psoriasis without PsA, & 22.7% concomitant PsA pts. Joint pain incr analgesic use (OR 3.72) #PsAlways https://t.co/WKrA8sChyN https://t.co/9FLq4mKz7V
Dr. John Cush @RheumNow( View Tweet )
Apr 01, 2022
RheumNow Podcast square

PsA All the Way – Unmet Needs

Apr 01, 2022

Throughout the month of April 2022, RheumNow is introducing a new approach to education and information sharing – a campaign devoted to a single disease. Our first campaign is entitled PsA All the Way: RheumNow will escalate awareness on this topic, its unmet needs, clarify advances and discuss

Read Article
Psoriasis Severe legs sara

Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis

Mar 29, 2022

Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.

Read Article
alopecia,areata,bald,hairloss

Baricitinib Efficacy in Alopecia Areata

Mar 28, 2022

The NEJM has published the results of the BRAVE-AA1 and BRAVE-AA2 trials, demonstrating that baricitinib is effective at regrowing hair in alopecia areata (AA) patients, thus paving the way for future regulatory approval for this difficult to treat disorder. 



Alopecia areata is an

Read Article
×